Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...